Loteplain-M

Loteplain-M is an ophthalmic combination suspension containing the corticosteroid loteprednol etabonate (0.5% w/v) and the fluoroquinolone antibiotic moxifloxacin (0.5% w/v). Developed by Centaur Pharmaceuticals, it is approved in India for the treatment of bacterial eye infections accompanied by inflammation, as well as for post-operative inflammation and infection prevention following ocular surgeries such as cataract extraction. Moxifloxacin acts as a broad-spectrum antibacterial agent by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, transcription, and repair. Loteprednol etabonate is a "soft steroid" designed to bind to glucocorticoid receptors and inhibit the synthesis of inflammatory mediators like prostaglandins. It is rapidly metabolized into inactive metabolites at the site of action, which minimizes the risk of steroid-induced intraocular pressure elevation and cataract formation compared to conventional corticosteroids.

Brand names

Loteplain-M

Other names

loteprednol + moxifloxacinloteprednol etabonate + moxifloxacinmoxifloxacin + loteprednolmoxifloxacin + loteprednol etabonate